Overview
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Description
This is an open-label study. The investigators propose to examine if BMS-986453 in people with newly diagnosed multiple myeloma may help control their disease for a prolonged period of time despite one-time treatment and challenge continuous treatment which is otherwise prescribed.
Eligibility
Inclusion Criteria:
- Age \> 18 years with no upper age limit
- NDMM with indication for initiation of therapy diagnosed within last 12 months. Pretreatment parameters necessary for disease characterization and response assessment must be available.
- Not eligible for ASCT by institutional criteria or deferring ASCT due to personal preference.
- ECOG performance status 0-1
- Adequate organ function
Exclusion Criteria:
- Known active or history of central nervous system (CNS) involvement of MM.
- Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS or clinically significant amiloidosis.
- Prior history of other malignancies
- Uncontrolled infection
Other protocol-defined Inclusion/Exclusion criteria apply.
